![Synthesis, in vitro anticancer screening and radiosensitizing evaluation of some new 4-[3-(substituted)thioureido]-N-(quinoxalin-2-yl)-benzenesulfonamide derivatives Cover](https://sciendo-parsed.s3.eu-central-1.amazonaws.com/6470750171e4585e08a9d8ce/cover-image.jpg)
References
- V. K. Tandon, D. B. Yadav, H. K. Maurya, A. K. Chaturvedi and P. K. Shukla, Design, synthesis, and biological evaluation of 1,2,3-trisubstituted-1,4-dihydrobenzo[g]quinoxaline-5,10-diones and related compounds as antifungal and antibacterial agents, Bioorg. Med. Chem. 14 (2006) 6120-6126; DOI: 10.1016/j.bmc.2006.04.029.
- S. Sehlstedt, P. Aich, J. Bergman, H. Vallberg, B. Nordén and A. Gräslund, Interactions of the antiviral quinoxaline derivative 9-OH-B220 {2,3-dimethyl-6-(dimethylaminoethyl)-9-hydroxy-6H-indolo-[2,3-b]quinoxaline} with duplex and triplex forms of synthetic DNA and RNA, J. Mol. Biol. 278 (1998) 31-56; DOI: 10.1006/jmbi.1998.1670.
- A. Carta, M. Loriga, G. Paglietti, A. Mattana, P. L. Fiori, P. Mollicotti, L. Mollicotti and S. Zanetti, Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-substituted-6,7-difluoro-3-methylquinoxaline 1,4-dioxides, Eur. J. Med. Chem. 39 (2004) 195-203; DOI: 10.1016/j.ejmech.2003.11.008.
- M. H. Fisher, A. Lusi and J. R. Egerton, Anthelmintic dihydroquinoxalino[2,3-b]quinoxalines, Eur. J. Med. Chem. 66 (1997) 1349-1352; DOI: 10.1002/jps.2600660942.
- A. Budakoti, A. R. Bhat and A. Azam, Synthesis of new 2-(5-substituted-3-phenyl-2-pyrazolinyl)-1,3-thiazolino[5,4-b]quinoxaline derivatives and evaluation of their antiamoebic activity, Eur. J. Med. Chem. 44 (2009) 1317-1325; DOI: 10.1016/j.ejmech.2008.02.002.
- R. S. Giri, H. M. Thaker, T. Giordano, J. Williams, D. Rogers, V. Sudersanam and K. K. Vasu, Design, synthesis and characterization of novel 2-(2,4-disubstituted-thiazole-5-yl)-3-aryl-3H-quinazoline-4-one derivatives as inhibitors of NF-κB and AP-1 mediated transcription activation and as potential anti-inflammatory agents, Eur. J. Med. Chem. 44 (2009) 2184-2189; DOI: 10.1016/j.ejmech.2008.10.031.
- J. S. Fisherman, B. L. Osborn and H. G. Chun, Chloroquinoxaline sulfonamide: A sulfanilamide antitumor agent entering clinical trials, Invest. New Drugs. 11 (1993) 1-9; DOI: 10.1007/BF00873904.
- F. Mohamadi, M. M. Spees and G. B. Grindey, Sulfonylureas: A new class of cancer chemotherapeutic agents, J. Med. Chem. 35 (1992) 3012-3016; DOI: 10.1021/jm00094a013.
- G. F. Rush, S. Rinzel, G. Boder, R. A. Heim, J. E. Toth and G. D. Ponsler, Effects of diarylsulfonylurea antitumor agents on the function of mitochondria isolated from rat liver and GC3/c1 cells, Biochem. Pharmacol. 44 (1992) 2387-2394; DOI: 10.1016/0006-2952(92)90684-B.
- M. M. Ghorab, F. A. Ragab, H. I. Heiba, R. K. Arafa and E. M. El-Hossary, In vitro anticancer screening and radiosensitizing evaluation of some new quinolines and pyrimido[4,5-b]quinolines bearing a sulfonamide moiety, Eur. J. Med. Chem. 459 (2010) 3677-3684; DOI: 10.1016/j.ejmech.2010.05.014.
- M. M. Ghorab, F. A. Ragab and M. M. Hamed, Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety, Eur. J. Med. Chem. 44 (2009) 4211-4217; DOI: 10.1016/j.ejmech.2009.05.017.
- M. M. Ghorab, F. A. Ragab, S. I. Alquasoumi, A. M. Alafeefy and S. A. Aboulmagd, Synthesis of some new pyrazolo[3,4-d]pyrimidine derivatives of expected anticancer and radioprotective activity, Eur. J. Med. Chem. 45 (2010) 171-178; DOI: 10.1016/j.ejmech.2009.09.039.
- P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenny and M. R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug screening, J. Natl. Cancer Inst. 82 (1990) 1107-1112; DOI: 10.1093/jnci/82.13.1107.
- M. S. A. El-Gaby, A. M. Hussein, F. A. M. Abu-Shanab and M. A. M. Abdel Raheim, some hitherto unknown thiosemicarbazide, thiourea, bisthiourea, benzoazole derivatives bearing quinoxalin-2-yl moiety and evaluate their biological activity, Afinidad 60 (2003) 358-369; DOI: 2780.35400011978567.0050.
- Y. Nishimura, Rationale for chemoradiotherapy, Int. J. Clin. Oncol. 9 (2004) 414-420; DOI: 10.1007/s10147-004-0443-z.